2006
DOI: 10.1016/j.euroneuro.2005.11.008
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
3
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 38 publications
2
3
0
Order By: Relevance
“…We here revealed a potential role of 5-HTT in cognitive deficits via the networks involved in socio-affective processes, resonating with the proposed implication of 5-HTT in the affective domain (87,88). While atypical anti-psychotics including olanzapine and risperidone target also the 5-HT2a serotonin receptor (89,90), their effects on 5-HTT seems to be equivocal (91,92).…”
Section: Molecular Architecture Of the Network Robustly Predicted Cosupporting
confidence: 77%
“…We here revealed a potential role of 5-HTT in cognitive deficits via the networks involved in socio-affective processes, resonating with the proposed implication of 5-HTT in the affective domain (87,88). While atypical anti-psychotics including olanzapine and risperidone target also the 5-HT2a serotonin receptor (89,90), their effects on 5-HTT seems to be equivocal (91,92).…”
Section: Molecular Architecture Of the Network Robustly Predicted Cosupporting
confidence: 77%
“…We here revealed a potential role of 5-HTT in cognitive deficits via the networks involved in socio-affective processes, resonating with the proposed implication of 5-HTT in the affective domain (87,88). While atypical anti-psychotics including olanzapine and risperidone target also the 5-HT 2a serotonin receptor (89,90), their effects on 5-HTT seems to be equivocal (91,92).…”
Section: Molecular Architecture Of the Identified Network Which Robusupporting
confidence: 77%
“…Clinically, chronic treatment (i.e. >3 weeks) with selective serotonin reuptake inhibitors (SSRIs) has been shown to reduce aggressive outbursts and violent behavior in psychiatric patients (Barkan et al 2006; Blader 2006; Bond 2005; Coccaro and Kavoussi 1997; New et al 2004; Reist et al 2003; Walsh and Dinan 2001). However, SSRIs have occasionally been reported to increase the incidence of aggressive and suicidal behavior, and the causes of these paradoxical effects remain unknown (Spigset 1999; Troisi et al 1995).…”
Section: Serotonin Transporter (5-htt)mentioning
confidence: 99%